BRCA1 and neoplasm: Preclinical studies indicate that the combination of the PI3K inhibitor Buparlisib (NVP-BKM120) and Olaparib delays tumor proliferation in mouse models for over 70 days and in BRCA1-related tumor xenograft models for over 50 days, suggesting that combined PI3K and PARP inhibition could be an effective treatment for BRCA1-related tumors (167).